Approval · Notice of Compliance 372 · 2003
CANCIDAS: Notice of Compliance 372
Issued July 11, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 372
- Date
- July 11, 2003
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication for the treatment of esophageal candidiasis
- Therapeutic class
- Antifungal
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CANCIDAS | Not yet assigned | — |
Medicinal ingredients
- CASPOFUNGIN ACETATE 70 MG per VIAL
- CASPOFUNGIN ACETATE 50 MG per VIAL